Cardiac effects of XXXX in endotoxemic @entity35 .

@entity1 @entity1331 @entity137 @entity25928 @entity326 @entity5637 @entity177 @entity364 @entity5626 @entity299 @entity35 @entity2827 @entity11794
UNASSIGNED: @entity5626 are known as effective and safe agents for the prophylaxis and treatment of different cohorts of @entity1 with @entity364 . Recent studies revealed that certain pharmacokinetics of @entity5637 antifungals might impact clinical efficacy and safety in special @entity1 populations. The aim of our study was to evaluate @entity5637 -induced aggravation of @entity299 in @entity326 . Using an in vivo endotoxemic shock model in @entity35 , we assessed hemodynamic parameters and time @entity177 ( @entity177 ) after additional central-venous application of @entity25928 (2.5 mg/kg body weight (BW), @entity11794 (0.875 mg/kg BW), @entity1331 (3 mg/kg BW and control (0.9% @entity2827 ). In addition, @entity5637 -induced @entity137 was evaluated in isolated @entity35 cardiac myocytes. @entity177 of the @entity11794 group animals (n=7) was significantly reduced compared to control (n=6) (136 min vs. 180 min; p=0.0209). @entity25928 group (n=7) also showed a trend to reduced @entity177 (136 min vs. 180 min; log-rank test p=0.0578). Animals of the @entity1331 group (n=7) did not show significant differences in @entity177 compared to control. Control group animals and also @entity1331 group animals did not show altered cardiac output (CO) during our experiments. In contrast, administration of @entity25928 or @entity11794 induced a decrease in CO. We also revealed a dose-dependent increase of @entity137 in @entity25928 and @entity11794 treated cardiac myocytes. Treatment with @entity1331 did not cause significant increased @entity137 . Further studies are needed to explore the underlying mechanism.
